About: An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
Creator	Koopmans, Marion Rahamat-Langendoen, Janette Haagmans, Bart Laksono, Brigitta Geurtsvankessel, Corine Leijten, Lonneke Okba, Nisreen Van Der Eijk, Annemiek Van Binnendijk, Rob Van Kampen, Jeroen Bogers, Susanne Embregts, Carmen Igloi, Zsofia Rijnders, Bart Rokx, Casper Van Den Akker, Johannes
Source	Medline; PMC
abstract	The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.1038/s41467-020-17317-y
bibo:pmid	32632160
has license	cc-by
sha1sum (hex)	4cd5ba631bdc68bea3a855a33ab2123d40e71f74
schema:url	https://doi.org/10.1038/s41467-020-17317-y
resource representing a document's title	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
has PubMed Central identifier	PMC7338506
has PubMed identifier	32632160
schema:publication	Nat Commun
resource representing a document's body	covid:4cd5ba631bdc68bea3a855a33ab2123d40e71f74#body_text
is schema:about of	named entity 'deployment' named entity 'screening' covid:arg/4cd5ba631bdc68bea3a855a33ab2123d40e71f74 named entity 'serological' named entity 'detailed' named entity 'receptor' named entity 'assays' named entity 'entering' named entity 'selected' named entity 'population' named entity 'indicating' named entity 'deciding' named entity 'immunoglobulins' named entity 'informs' named entity 'immunoglobulins' named entity 'wide diversity' named entity 'antibody testing' named entity 'exposure assessment' named entity 'informs' named entity 'deployment' named entity 'antibody' named entity 'HCoV-229E' named entity 'ELISAs' named entity 'IgG' named entity 'travel restrictions' named entity 'antibody' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'ELISAs' named entity 'antibodies' named entity 'case finding' named entity 'seroconversion' named entity 'SARS-CoV-2' named entity 'antibodies' named entity 'SARS' named entity 'antibody' named entity 'IgG' named entity 'IgA' named entity 'OC43' named entity 'clinical data' named entity 'IgG' named entity 'IgA' named entity 'PPV' named entity 'fingerstick' named entity 'Saluggia' named entity 'functional antibody' named entity 'PCR based' named entity 'SARS-CoV-2' named entity 'Netherlands' named entity 'GraphPad Prism' named entity 'PPV' named entity 'time interval' named entity 'Rapid Test' named entity 'seroprevalence' named entity 'viruses' named entity 'antibody' named entity 'SARS' named entity 'rapid tests' named entity 'antigens' named entity 'serum' named entity 'RDT' named entity 'seroprevalence' named entity 'RT-PCR' named entity 'protective antibodies' named entity 'COVID' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software